Shattuck Labs Inc (STTK)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$4.49-12.82%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · STTK
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
• Initiated the RECEPTIVE-CD1 Phase 2b clinical trial of SL-325 in patients with moderately-to-severely active Crohn's disease.
Stated in 3 of 3 supplied quarters. Management reported: “• Initiated the RECEPTIVE-CD1 Phase 2b clinical trial of SL-325 in patients with moderately-to-severely active Crohn's disease.” “• Announced plans to initiate the RECEPTIVE-HS1 Phase 2 clinical trial of SL-325 in patients with moderate to severe hidradenitis suppurativa, with trial initiation expected in the fourth quarter of 2026.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 29% of the time over the next year (vs 52% for the rest of the cohort, n=10118).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“• Initiated the RECEPTIVE-CD1 Phase 2b clinical trial of SL-325 in patients with moderately-to-severely active Crohn's disease.”
“• RECEPTIVE-CD1 Phase 2b clinical trial of SL-325 in patients with moderately-to-severely active Crohn's disease is expected to initiate in the third quarter of 2026.”
“• Subject to positive Phase 1 data and regulatory alignment, Shattuck expects to initiate a Phase 2 clinical trial of SL-325 in patients with Crohn’s disease in the third quarter of 2026.”
• Shattuck expects to initiate a Phase 1 healthy volunteer clinical trial of SL-846 and report initial data in 2027.
Stated in 3 of 3 supplied quarters. Management reported: “• Shattuck expects to initiate a Phase 1 healthy volunteer clinical trial of SL-846 and report initial data in 2027.” “• Presented preliminary preclinical data for SL-846 at UEG Week 2026, including data from the GLP toxicology study in non-human primates, which showed the following: ◦ Well tolerated through the top dose of 100 mg/kg.”
“• Shattuck expects to initiate a Phase 1 healthy volunteer clinical trial of SL-846 and report initial data in 2027.”
“• Shattuck expects to initiate a Phase 1 healthy volunteer clinical trial of SL-846 and report initial data in 2027.”
“Shattuck’s lead bispecific antibody has entered IND-enabling activities.”
Shattuck’s current cash and cash equivalents, and short-term investments are expected to fund operations into 2029.
Stated in 3 of 3 supplied quarters. Management reported: “Shattuck’s current cash and cash equivalents, and short-term investments are expected to fund operations into 2029.” “Third Quarter 2026 Financial Results • Cash and Cash Equivalents and Investments: As of September 30, 2026, cash and cash equivalents and short-term investments were $196.3 million, as compared to $86.1 million as of September 30, 2025.”
“Shattuck’s current cash and cash equivalents, and short-term investments are expected to fund operations into 2029.”
“Shattuck’s current cash and cash equivalents, and short-term investments are expected to fund operations into 2029.”
“Shattuck’s current cash and cash equivalents, assuming the full exercise of the outstanding common stock warrants, are expected to fund operations into 2029.”
Initiate and progress the Phase 2b clinical trial of SL-325, a DR3 blocking antibody, to establish efficacy and safety in Crohn's disease patients.
Shattuck aims to fund its operations into 2029 through current cash, cash equivalents, and stock warrants.
Over the trailing year it converted 0.94x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates (low R² over the window).
6 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated stable grew net income 43% of the time over the next year (vs 45% for the rest of the cohort, n=9530).
Not investment advice. As of 2026-11-05.